Treatment of t-cell mediated immune disorders

Abstract

A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1 + cells and/or soluble factors derived therefrom to suppress T cell activation.

1 . A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1 +  cells and/or soluble factors derived therefrom to suppress T cell activation. 
     
     
         2 . A method according to  claim 2  wherein the cell population is a peripheral blood mononuclear cell sample. 
     
     
         3 . A method according to  claim 2  wherein the cell population comprise CD25 +  CD4 +  T cells of a naïve phenotype (CD45RA + ). 
     
     
         4 . A method according to any one of  claims 1  to  3  which comprises contacting the cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1 +  cells and/or soluble factors derived therefrom and one or more factors which induce formation of regulatory T cells. 
     
     
         5 . A method according to  claim 4  wherein the one or more factors which induce formation of regulatory T cells is selected from the group consisting of a-melanocyte-stimulating hormone (α-MSH), transforming growth factor-β2 (TGF-β2), vitamin D3 and/or Dexamethasone. 
     
     
         6 . A method according to any one of  claims 1  to  4  which further comprises contacting the cell population comprising T cells with one or more agents selected from the group consisting of interleukins, antigens, antigen presenting cells, lectins, and antibodies or specific ligands for a cell surface receptors or combinations thereof. 
     
     
         7 . The method according to  claim 6  wherein the interleukin is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 or combinations thereof. 
     
     
         8 . A composition of T cells obtained by the method of any one of  claims 1  to  7 . 
     
     
         9 . A composition comprising T cells, STRO-1 +  cells and/or soluble factors derived therefrom, one or more factors which induce formation of regulatory T cells and a pharmaceutically acceptable carrier. 
     
     
         10 . A method for treating an autoimmune disorder in a subject in need thereof comprising treating a cell population comprising T cells in vitro or ex vivo with an effective amount of STRO-1 +  cells and/or soluble factors derived therefrom to suppress T cell activation and administering the treated cells to the subject. 
     
     
         11 . A method for treating or preventing a disorder caused by excessive or aberrant T cell activation comprising administering to a subject in need thereof an amount of STRO-1 +  cells and/or soluble factors derived therefrom effective to suppress T-cell activation in the patient. 
     
     
         12 . The method of  claim 10  or  claim 11 , comprising administering between 0.1×10 6  to 5×10 6  STRO-1 +  cells and/or progeny thereof. 
     
     
         13 . The method of any one of  claims 10  to  12 , comprising administering between 0.3×10 6  to 2×10 6  STRO-1 +  cells and/or progeny thereof. 
     
     
         14 . The method of any one of  claims 10  to  12  comprising administering a low dose of STRO-1 +  cells and/or progeny thereof. 
     
     
         15 . The method of  claim 14 , wherein the low dose of STRO-1 +  cells and/or progeny thereof comprises between 0.1×10 5  and 0.5×10 6  STRO-1 +  cells and/or progeny thereof. 
     
     
         16 . The method of  claim 14 , wherein the low dose of STRO-1 +  cells and/or progeny thereof comprises about 0.3×10 6  STRO-1 +  cells and/or progeny thereof. 
     
     
         17 . A method according to any one of  claims 10  to  16  which further comprises administering to the subject one or more agents selected from the group consisting of interleukins, antigens, antigen presenting cells, lectins, and antibodies or specific ligands for a cell surface receptors or combinations thereof. 
     
     
         18 . The method according to  claim 17  wherein the interleukin is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 or combinations thereof. 
     
     
         19 . The method according to any one of  claims 10  to  18 , further comprising administering an immunosuppressive drug to the subject. 
     
     
         20 . A method according to claim any one of  claims 1  to  19  wherein the STRO-1 +  cells are enriched for STRO-1 bright  cells. 
     
     
         21 . A method according to any one of  claims 1  to  20  wherein the STRO-1 bright  cells and/or progeny thereof are allogeneic.